Study Watch Sleep Metric Performance Characterization Study

Inclusion Criteria:

• Participant is ≥ 18 and ≤ 80 years old
• Participant understands the study requirements and is able and willing to providewritten informed consent
• Participant is without significant limitation in ability to participate in the study,in the opinion of the investigator
• Participant belongs to one of the following participant groups as determined byscreening questionnaires:
• Typical sleepers (i.e., STOP-Bang score of 0-2 or OSA50 < 5, Insomnia SeverityIndex (ISI) < 8, and Epworth Sleepiness Scale (ESS) < 10), and no evidences ofsleep-disordered breathing at the PSG evaluation
• Insomnia sleepers (i.e., ISI > 10 and PSG AHI < 5)
• Sleep apnea sleepers (i.e., STOP-Bang score of 3-8 or OSA50 ≥ 5) or moderate tosevere obstructive sleep apnea (PSG AHI ≥5))
• Participant has agreed to abstain from caffeine, nicotine, alcohol, and cannabisproducts for 8 hours prior to the In-Lab Screening Visit and until the visit iscompleted
• Exception - unless the participant use of product has approval from the PrincipalInvestigator
• Participant has agreed to abstain from OTC or PRN medications that are not regularlyused on a daily basis and may affect sleep/wakefulness for 24 hours prior to theIn-Lab Overnight Visit and during the study visit
• Exception - unless the participant uses OTC or PRN medication on a routine basisand has approval from the Principal Investigator

Exclusion Criteria: Conditions based on self-report of having been told by a doctor of aformal diagnosis

• Presence of any of the following diagnosed sleep, medical, or psychiatric disorders:
• Sleep
• Narcolepsy
• Restless leg syndrome
• Circadian rhythm sleep disorder
• Periodic Limb Movement Disorder
• REM Sleep behavior disorder
• Medical
• Epilepsy or other seizure disorder
• Renal failure or chronic kidney disease
• Acute or chronic infection that may interfere with the study
• Movement neurological disorder that impairs movement or autonomic stability (e.g. Parkinson's disease, Huntington's disease)
• Cardiopulmonary diseases (e.g. heart failure, chronic obstructive pulmonarydisease, ventilatory disorders)
• Persistent arrhythmias and dysrhythmias
• Severe neuromuscular disease (e.g. Amyotrophic lateral sclerosis [ALS])
• Psychiatric
• Severe significant mood disorder (e.g. depression, bipolar disorder)
• Substance use disorder
• Participant uses supplemental oxygen during the day or night
• Participant is unwilling to cease use of CPAP or oral appliance for sleep-disorderedbreathing during the In-Lab Overnight Visit; or cessation is deemed to be ofsubstantial risk in the opinion of the Principal Investigator
• Women who are pregnant, lactating, or breastfeeding
• Participant takes prescription stimulants, sedatives, opioids, alpha blockers, shortacting nitrates, or any other medication that, in the opinion of the PrincipalInvestigator and study team, impacts their sleep behavior
• Use of any sleep medications (over-the-counter or prescription) in the previous 24hours for Typical Sleepers
• Participant has a cardiac pacemaker, implantable defibrillator, medical pump, or otherimplantable medical electronic device
• Participant has Shift Work Sleep Disorder (SWSD) or is a night-shift worker
• Participant has traveled >3 time zone within two weeks prior to study
• Participant is not fluent at reading and speaking English
• Participant is deemed not to be a candidate for the study, in the opinion of thePrincipal Investigator
• Known severe allergy to nickel or metal jewelry
• Open injury or rash where the study device or comparator will be worn
• Known severe allergy to polyester, nylon, or spandex material
• Enrolled participants who meet exclusion criteria after PSG, upon confirmation withthe principal investigator and study team, will be discontinued and excluded fromprimary analyses.